PEDRO PIEDRA to Cost-Benefit Analysis
This is a "connection" page, showing publications PEDRO PIEDRA has written about Cost-Benefit Analysis.
Connection Strength
0.044
-
Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines. Clin Infect Dis. 2017 Sep 15; 65(6):1020-1025.
Score: 0.029
-
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007 Nov 19; 25(47):8010-20.
Score: 0.015